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Impulsivity in cocaine-dependent individuals with and without attention-deficit/ 
hyperactivity disorder 
 
Abstract 
 
Background: Cocaine-dependent individuals (CDI) display increased impulsivity. Despite its multi-
factorial nature however, most studies in CDI have treated impulsivity monolithically. Moreover, the 
impact of attention-deficit/hyperactivity disorder (ADHD) has often not been taken into account. This 
study investigates whether CDI+ADHD differ from CDI without an ADHD diagnosis and healthy 
controls (HC) on several impulsivity measures. Methods: 34 CDI, 25 CDI+ADHD and 28 HC 
participated in this study. Trait impulsivity was assessed with the motor, attentional and non-planning 
subscales of the Barratt Impulsiveness Scale (BIS-11). Neurocognitive dimensions of impulsivity were 
examined with the stop signal task (SST), delay discounting task (DDT) and information sampling task 
(IST). Results: Relative to HC, both CDI and CDI+ADHD scored higher on all BIS-11 subscales, 
required more time to inhibit their responses (SST) and sampled less information before making a 
decision (IST). Greater discounting of delayed rewards (DDT) was only found among CDI+ADHD. 
Compared to CDI without ADHD, CDI+ADHD scored higher on the BIS-11 non-planning and total 
scale and showed higher discounting rates. Conclusion: CDI score higher on several indices of 
impulsivity relative to HC, regardless of whether they have concomitant ADHD. CDI+ADHD are 
specifically characterized by a lack of future orientation compared to CDI without ADHD.  
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1. Introduction 
Impulsivity is among the most common diagnostic criteria in the Diagnostic and Statistical 
Manual for Mental Disorders (DSM-5) [1]. Although the construct has been predominantly approached 
from a personality perspective (i.e., trait impulsivity) [2,3], growing scientific interest has been noted for 
impulsivity in neurocognitive research [4]. At a neurocognitive level, a distinction is often made 
between two types of impulsivity; impulsive action and impulsive choice [5]. Impulsive action refers to 
failures to withhold/suppress inappropriate/prepotent actions, thus reflecting poor response inhibition 
[5,6]. Impulsive choice on the other hand, refers to impulsive decisions, often resulting from a distorted 
evaluation of delayed consequences. Delay discounting for instance, occurs when the subjective value 
of an outcome decreases because its delivery is delayed and is typically indexed by an individual’s 
preference for smaller immediate rewards relative to larger delayed rewards. Another often-overlooked 
aspect of impulsive choice, reflection impulsivity, refers to the tendency not to collect and evaluate 
enough information before making complex decisions [7]. Importantly, the distinction between 
impulsive action and impulsive choice has been justified by neurobiological evidence supporting 
distinct cortico-striatal substrates underlying both dimensions of impulsivity [8]. 
Impulsivity is a hallmark characteristic of substance use disorders (SUDs) in general, and of 
cocaine dependence in particular [9]. Over the years, several studies have shown that cocaine-
dependent individuals (CDI) demonstrate notable deficits on tasks indexing aspects of impulsive action 
and impulsive choice. On laboratory paradigms of motor inhibition for instance, chronic cocaine users 
typically display a lower probability of inhibiting their responses and require more time to inhibit their 
responses to stop signals compared to healthy controls (HC) [10]. In addition, CDI have been found to 
discount delayed monetary rewards more steeply than do non-drug-using controls, suggesting higher 
levels of impulsive choice in this group [11,12,13]. Notably, recent studies have established the clinical 
relevance of impulsivity in substance-dependent individuals. In particular, elevated levels of impulsive 
action and choice at treatment onset have been found to predict poor addiction treatment outcomes 
[14,15]. For example, higher levels of impulsive choice in CDI were recently identified as a significant 
predictor of premature drop-out from treatment in a therapeutic community [16]. These and other 
findings suggest that treatment outcomes for CDI may be improved by targeting impulsivity.  
Whereas the relationship between cocaine dependence and impulsivity is rarely disputed, 
impulsivity research in substance-dependent individuals in general and CDI specifically has historically 
been slowed due to the absence of a uniformly agreed-upon definition of the construct impulsivity. As 
noted previously, there is substantial empirical evidence indicating that impulsivity is a multi-factorial 
construct comprised of several related components [17,18,19,20]. In addition, these different 
components of impulsivity appear to recruit different brain circuitries and may be susceptible to diverse 
pharmacological influences [21]. Although these findings suggest that elucidating which impulsivity 
aspects are more relevant to cocaine dependence than others may have important treatment 
implications, relatively little research has evaluated various aspects of impulsivity in CDI 
simultaneously. Rather, most studies have been conducted in separate groups, each performing 
impulsivity paradigms targeting impulsive action or impulsive choice independently. Whereas these 
studies demonstrate that cocaine dependence is associated with both impulsive action [11] and 
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impulsive choice [11,12], direct comparisons should be interpreted with caution because of major 
differences in the sample characteristics of these studies (e.g., age, clinical vs. general population, 
duration of cocaine use, cocaine use severity, etc). In addition, most previous studies in cocaine users 
have not taken into account the effects of other disorders that are known to adversely affect impulsivity 
in a fashion similar to cocaine addiction. Indeed, trait impulsivity and impairments in impulsive action 
and impulsive choice are not specific to cocaine dependence but have been considered as risk factors 
common to all externalizing disorders, including bipolar, antisocial and borderline personality disorders 
[22,23]. High impulsivity is also considered a core feature of attention deficit/hyperactivity disorder 
(ADHD) [5,24,25,26,27,28,29], a developmental disorder that frequently co-occurs with cocaine 
dependence [30]. Indeed, estimates of co-morbidity between cocaine dependence and ADHD in 
addiction treatment settings typically range from 10% to 35% [31,32,33,34]. Given the high prevalence 
of ADHD in chronic cocaine users, ADHD might be a significant confounding factor when examining 
neurocognition in general and impulsivity in particular among CDI. It might be questioned for instance 
whether higher levels of impulsive action and impulsive choice in CDI are specifically associated with 
the presence of a comorbid ADHD diagnosis. Alternatively, ADHD may have an additive effect on 
impulsivity in CDI. In support of the latter hypothesis, a study in gamblers found that the comorbidity of 
ADHD and problem gambling was associated with higher trait impulsivity relative to problem gambling 
without ADHD [35]. As both impulsivity as well as the presence of ADHD among CDI have been found 
to predict worse addiction treatment outcomes [15,16,36,37,38], elucidating the specific impulsivity 
profile of CDI with ADHD may be of significant clinical relevance.  
With the present study, we sought to investigate multiple indices of impulsivity among a 
sample of CDI and explore the effects of ADHD on impulsivity in this group. In accordance with the 
multi-factorial nature of impulsivity, three neurocognitive tasks indexing dissociable dimensions of 
impulsivity and a personality questionnaire measuring three different components of trait impulsivity 
were administered to a group of CDI, CDI+ADHD and HC. Both clinical groups were expected to show 
enhanced impulsivity relative to non-drug-using controls. Since impulsivity is one of the hallmarks of 
ADHD, our second hypothesis was that CDI with an ADHD diagnosis would present more pronounced 
deficits on several indices of impulsivity when compared to CDI without ADHD. 
 
2. Methods 
2.1. Setting and Participants 
A total of 87 individuals participated in this study. Fifty-nine of these were CDI, who were all recruited 
from inpatient detoxification programs. All centers required complete abstinence from drugs and 
alcohol, with the exception of caffeine and nicotine. Aside from scheduled activities (e.g., group 
activities such as physical exercise, physician visits), residents were not permitted to leave the center 
grounds during treatment. Regular drug testing was further provided and any substance use was 
grounds for dismissal from the detoxification center. Based on a screening questionnaire and 
diagnostic interview (see 2.2. Assessments), thirty-four were classified as CDI without ADHD, and 25 
were classified as CDI with an ADHD diagnosis. None of the participants in the latter group were being 
treated with psycho-stimulants at the time of assessment. Residents were approached for participation 
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by the staff members within the first 4 days of their arrival at the detoxification center. In order to 
participate in the current study, individuals had to meet the DSM-IV criteria for cocaine dependence at 
the time of admission to the treatment program and report cocaine as their primary substance of 
abuse. Individuals were excluded if they had (1) past or current major DSM diagnosis of psychotic 
disorders; (2) a history of neurological condition, such as strokes, intracranial hemorrhages and/or 
head injuries with loss of consciousness for longer than 30 min; (3) an intellectual quotient (IQ) lower 
than 70 and; (4) insufficient comprehension of the Dutch language to understand test instructions. 
Eligible participants were interviewed and tested within the first week from starting treatment (range 3–
8 days). All CDI had a minimum of three days of abstinence (range = 3-60 days, mean = 12.62 days, 
SD = 12.01) at the time of assessment. Trait impulsivity scores and neurocognitive performance of the 
CDI were compared to a control group of 28 healthy individuals, who were volunteers, recruited by 
word of mouth from the community. The exclusion criteria for the control group were: (1) meeting 
DSM-IV criteria for any psychoactive substance dependence other than nicotine; (2) having a positive 
ADHD interview and (3) the above-mentioned exclusion criteria for the CDI. Ethical approval for the 
study was granted by the Ethical Review Board of the Faculty of Psychology and Educational 
Sciences at Ghent University. 
 
2.2. Assessments 
 
2.2.1. Background and drug use characteristics 
A demographic form was used to collect basic demographic information (e.g., age, gender, education). 
Information regarding drug use, including the presence of poly-drug use (i.e., concomitant or 
consecutive use of various licit or illicit drugs, with the exclusion of pharmacological agents), was 
assessed using a Dutch translation of the European version of the Addiction Severity Index (ASI), a 
semi-structured clinical assessment interview [39,40]. The psychometric properties of the ASI are well 
established with strong retest reliability and concurrent, predictive, and discriminate validities [41]. 
Additional information about the frequency and duration of drug use was collected using the Interview 
for Research on Addictive Behavior [42]. To make a timesaving but accurate estimation of the current 
intellectual abilities, IQ was estimated using two subtests of the Wechsler Adult Intelligence Scale, 
third edition [43]: matrix reasoning and information. This dyadic short form has been found to be 
appropriate for obtaining a good estimate of full scale IQ in a psychiatric sample: the estimated IQ 
derived from the administration of this short form has a correlation of .92 with the full scale IQ [44]. 
 
2.2.2. ADHD assessment 
For the screening of ADHD in the CDI, the ADHD Rating Scale (ARS) [45] was used. The ARS is a 
self-report rating scale, which includes all the 18 DSM-IV items on inattention, hyperactivity, and 
impulsivity. The questionnaire screens for the presence of symptoms in both childhood and adulthood. 
In the Dutch version of the ARS, five DSM-IV items containing double statements were reformulated in 
two statements, so that the total number of items was 2 x 23. In the analyses, the 23 item scores were 
recalculated to the original 18 DSM-IV items. Each of the 46 items is scored on a 4-point likert scale 
ranging from 0 (rarely or never) to 3 (very often). A symptom was considered as present if the answer 
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given to the item was ‘often’ or ‘very often’ (score of 2 or 3). Whereas a less stringent cut-off score of 4 
DSM-IV criteria has been recommended for adults [45,46], we used the more stringent cut-off score of 
6 symptoms for both childhood and adulthood symptoms. This cut-off score was applied to avoid over-
diagnosing ADHD, as symptoms associated with intoxication or withdrawal may mimic ADHD 
symptoms. The ADHD Rating Scale has been used in epidemiological and clinical research in adults 
[45]. Internal consistency of the ARS scales in our sample was high (Cronbach’s alpha = .84-.94) (see 
Table 2), and the consistency of the Inattention scale was higher than that of the 
Hyperactivity/Impulsivity scale. Positive screening results, i.e., 6 or more symptoms of either 
inattention or impulsivity/hyperactivity during both childhood and adulthood, were followed by a 
diagnostic interview using the separate ADHD-module of the Mini-International Neuropsychiatric 
Interview (M.I.N.I.Plus) [47]. A M.I.N.I.Plus–derived ADHD diagnosis is established if, prior to the age 
of 7, a subject meets 6 of 10 criteria for ADHD and, during adult years, a subject meets 9 of 14 criteria. 
Similar to the DSM-criteria, the M.I.N.I.Plus requires impairment from the symptoms to be present in 
two or more settings. The instrument does not differentiate between inattentive and hyperactive 
subtypes.  
 
Definition of CDI and CDI+ADHD  
Only subjects who had a positive ARS screener (i.e., those who reported 6 or more symptoms of 
either inattention or impulsivity/hyperactivity during both childhood and adulthood) and fulfilled 
confirmation of adult ADHD diagnosis using the ADHD-module of the M.I.N.I.Plus were assigned to 
the CDI+ADHD group. Of the 59 CDI who were screened, 27 subjects screened positive using the 
ARS. Of these, 25 met the criteria for ADHD using the ADHD-module of the M.I.N.I. Accordingly, 25 
subjects were assigned to the CDI+ADHD group. All the remaining subjects (n=34), who were either 
screen negative (n=32) or interview negative (n=2), were included in the CDI without ADHD group. In 
HC, the presence of ADHD was excluded using the ADHD-module of the M.I.N.I.Plus.  
2.2.3. Impulsivity 
2.2.3.1. Self-report questionnaire 
The Barratt Impulsiveness Scale, version 11 (BIS-11) [48] is a self-report questionnaire consisting of 
30 items, with responses on a four-point Likert-type scale ranging from “rarely/never” to “almost 
always/always”. The questionnaire measures three distinct trait dimensions of impulsivity: attentional 
impulsiveness, motor impulsiveness, and non-planning impulsiveness. These three domains yield 
three subscores, which can be summed to yield a total score. Cumulative scores range from 30 (low in 
trait impulsivity) to 120 (high in trait impulsivity). The questionnaire has been shown to be reliable in 
both clinical and population-based samples, with Cronbach’s alpha coefficients ranging from .79 to .83 
[48]. Cronbach’s alpha of the total BIS score in the present study was .79. Cronbach alpha’s for non-
planning, motor and attentional impulsivity were .67, 62 and .39, respectively.  
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2.2.3.2. Neurocognitive tasks  
Impulsive action: Inhibition of a pre-potent response was measured by a stop signal task (SST), 
operated using E-Prime experiment generation software [49]. A total of 240 trials were presented with 
a go/stop ratio of 80/20, of which the first 60 trials served as practice trials to obtain stable 
performance (not included in the analyses). Go-trials require the subjects to react as quickly as 
possible to a series of left- or rightward pointing airplanes appearing on the screen by pressing a 
corresponding key (“left” or “right”). This speeded reaction time task establishes a prepotency to 
respond. On a subset of trials, the go-stimulus is followed, after a variable delay, by a visual stop-
signal (i.e., a cross) presented on top of the airplane, to which participants are instructed to inhibit their 
response. Stop-signals were presented using a tracking algorithm [49], a procedure which dynamically 
adjusts the delay at which the stop-signal appears after the onset of the go-signal (i.e., the 
presentation of the airplane) to control inhibition probability. This algorithm ensures a 50% rate of 
successful inhibition for each subject and compensates for differences in choice reaction time between 
participants. The main dependent variable reflecting inhibitory control, the stop signal reaction time 
(SSRT), reflects the time needed to inhibit the pre-potent response once the stop-signal occurs. 
Longer SSRTs therefore reflect worse inhibitory control. Secondary measures included mean reaction 
time (MRT) to go-stimuli and intra-individual variability in reaction times to go-stimuli, as indexed by 
the coefficient of variation (CV) (= SDMRT/MRT). 
 
Impulsive choice: The delay discounting task (DDT) was administered in order to measure the 
preference for small immediate rewards over large delayed rewards [50]. Subjects had to make 
preference judgments between a future and an immediate hypothetical monetary reward. The task 
consisted of six blocks with eight preference judgments per block. The future reward was the same for 
all trials of a given block, with a block-specific delay in days (i.e., 5, 30, 180, 365, 1095, 3650). The 
immediate reward varied in magnitude from trial to trial, depending on the responses made by the 
subjects [50]. The indifference points, indicating which immediately delivered amount of money would 
be preferred equally to the delayed reward, obtained for each delay were plotted and hyperbolic 
discount functions were derived through curve-fitting analysis. The k-value, which indexes the degree 
of delay reward discounting, was used as the dependent variable; as k increases, the person 
discounts the future reward more steeply and thus higher k-values correspond to higher levels of 
impulsive choice.  
 
The information sampling task (IST) [7] was used to index reflection impulsivity. This dimension of 
impulsive choice refers to the tendency to gather and evaluate information before making a decision. 
The IST presents a series of trials with an array of 25 grey boxes, with two larger colored panels (e.g., 
red and blue) below at the foot of the screen. Upon being selected, boxes open to reveal one of these 
two colors. On each trial, subjects had to decide which of the two underlying colors were in the 
majority. Two conditions were presented: in the fixed win (FW) condition, subjects could win 100 
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points for correct choices or lose 100 points for incorrect choices, regardless of the number of boxes 
opened. Subjects did not lose points by opening boxes. In the decreasing win (DW) condition, the 
possible number of points for a correct answer started at 250, and the number of available points 
decreased by 10 with every box opened. Thus, subjects could win more points for earlier decisions. 
The penalty for a wrong choice remained the same at 100 points. The primary outcome measures 
were the average number of boxes opened and the probability (P) of the subject being correct at the 
point of decision in each condition [7]. This P(correct) is highly correlated with the number of boxes 
opened but provides a more sensitive measure of the information available at the time of decision (i.e., 
it is more directly related to the levels of certainty tolerated during decision-making). A higher number 
of boxes opened and higher P(correct)-values indicate less impulsivity.  
 
2.3. Data analysis 
Initial data analysis involved assessing differences between the three groups on demographic (e.g., 
gender, age, education) and clinical variables (i.e., IQ), using parametric or non-parametric statistics 
as appropriate. For drug-related variables, independent t-tests were used to compare the two cocaine 
groups on continuous variables, and chi-square tests for dichotomous variables (e.g., poly-drug use). 
Healthy controls were not included in these analyses, because their drug use values were always 0. In 
order to assess group differences related to impulsivity, univariate (e.g., BIS-11 total scores), 
multivariate (e.g., BIS-11 subscales) or repeated measures ANOVA’s (e.g., IST) were performed 
followed by post-hoc Bonferroni testing when the ANOVA revealed a significant group effect. Variables 
that significantly differed between the HC and groups of cocaine users (i.e., IQ and years of education) 
or between the two cocaine groups (i.e., poly-drug-use) were entered as covariates in all analyses. To 
assess the degree to which indices of impulsivity discriminated between CDI with and without ADHD, 
a logistic regression analysis was conducted on the impulsivity variables that demonstrated significant 
between-group differences, with ADHD status as the dependent variable. Predictive accuracy was 
summarized using standard descriptors, including sensitivity and specificity. Correlations between 
impulsivity measures and cocaine use variables in the cocaine groups were assessed using Pearson 
product-moment correlations. All statistical analyses were conducted using the Statistical Package for 
the Social Science (SPSS) software version 22. 
 
3. Results 
3.1. Background information   
Socio-demographic and some clinical characteristics of the three groups are summarized in Table 1. 
Chi-square analysis revealed a trend for differences in the distribution of male and female participants. 
The three groups did not differ significantly on age. However, HC had a significantly higher number of 
years of education and higher IQ-scores as compared to CDI and CDI+ADHD. The two clinical groups 
did not differ significantly from one another on these variables.  
Independent t-tests revealed that both cocaine groups did not significantly differ from one another in 
terms of their age of cocaine onset, past month cocaine use and duration of cocaine use (years) (see 
Table 1). They also showed a similar pattern of past month use for other substances, such as alcohol, 
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marihuana, opiates and amphetamines. The two groups did not differ in terms of their mean days of 
abstinence (i.e., reported length of time since the last use of cocaine at the time of the testing). 
However, poly-drug use was significantly more prevalent in the comorbid group, with 92% of these 
comorbid subjects reporting using multiple substances simultaneously (as compared to 62% in the 
non-comorbid group). 
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Table 1: Group characteristics of HC, CDI and CDI with ADHD 
 Variables HC (n=28) CDI (n=34) CDI+ADHD 
(n =25) 
Test statistic 
Demographics Gender (M:F) 19/9 29/5 23/2 [X
2
(2) = 5.63, p = .06] 
Age 30.39 ± 9.77 30.79 ± 5.90 28.04 ± 7.53 [F(2,49) = 1.16, p = .32] 
Education (years) 14.36 ± 2.11 12.53 ± 2.27 11.32 ± 2.25 [F(2,84) = 12.74, p < .001] 
Clinical  IQ 108.54 ± 12.23 88.71 ± 9.43 86.40 ± 7.57 [F(2,84) = 41.76, p < .001] 
Cocaine use 
  
Age of first cocaine use NA 20.12 ± 4.98 18.48 ± 3.92 [t(57) = 1.36, p = .18] 
Cocaine use past month (days) NA 16 ± 11.50 13.12 ± 10.93 [t(57) = .97, p = .34] 
Duration of cocaine use (years) NA 8.18 ± 7.53 7.44 ± 6.49 [t(57) = .393, p = .70] 
Alcohol and other substances 
(past month) 
 
 
 
 
 
Alcohol (days) - 13.21 ± 12.55 14.88 ± 11.19 [t(57) = -.53, p = .60] 
Marihuana (days) / 5.18 ± 10.56 10.88 ± 13.85 [t(43) = -1.72, p = .09] 
Opiates (days) / / .92 ± 4.02 [t(57) = -1.34, p = .19] 
Amphetamines (days) / 1.47 ± 5.48 1.64 ± 6.03 [t(57) = -.112, p = .91] 
Poly-drug use (%) NA 62% 92% [X
2
(1) = 6.95, p = .01] 
Abstinence (days) NA 12.15 ± 9.87 13.24 ± 14.56 [t(57) = -.339, p = .74] 
Data are presented as means ± SD, unless otherwise indicated. M: male, F: female. 
NA: Not applicable 
- Information not available  
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In order to fully characterize differences between the CDI and CDI+ADHD group, Table 2 displays the 
number of ADHD symptoms on the ARS for both groups, with the two domains of inattention and 
hyperactivity-impulsivity scored separately. As expected, differences between both groups in terms of 
their mean number of ADHD symptoms during childhood and adulthood were highly significant and 
showed large effect sizes (r), ranging from .49 to .75. 
 
Table 2: Cronbach alpha’s (α) and number of ADHD symptoms in CDI and CDI+ADHD, for both inattention (IA) 
(0-9) and hyperactivity/Impulsivity (HI) (0-9) on the ADHD Rating Scale (ARS). 
Data are presented as means ± SD. 
 
3.2. Impulsivity 
3.2.1. Impulsivity across groups 
3.2.1.1. Self-report questionnaire 
The results of the BIS-11 self-report questionnaire data are presented in Table 3. One-way ANOVA of 
BIS-11 total scores revealed a significant main effect of group, due to increased scores in the two 
clinical groups relative to the HC (both p < .001). This effect remained significant while controlling for 
differences in IQ (see Table 3) or years of education (p < .001). Post-hoc comparison further revealed 
significantly higher BIS-11 total scores in the comorbid relative to the non-comorbid group of CDI, 
which remained significant when taking into account the effects of poly-drug use (F(1,56) = 13.64, p < 
.001, ES = .44). Multivariate ANOVA of the subscale ratings showed a significant overall group effect 
while taking into account differences in IQ (Wilks’ Lambda = 10.68, p < .001) or years of education 
(Wilks’ Lambda = 8.96, p < .001), with significant univariate effects on the motor, attentional, and non-
planning subscales (see Table 3). The two clinical groups scored higher on all three subscales relative 
to HC (all p < .001). In addition, post-hoc comparison revealed significant differences between the CDI 
and CDI+ADHD on the non-planning subscale, on which the comorbid group scored significantly 
higher than the CDI-only group. Differences between the two clinical groups on the non-planning 
subscale remained significant when controlling for the effects of poly-drug use (F(1,56) = 18.25, p < 
.001, ES = .50). 
 
ARS Scales Cronbach 
α 
CDI 
 
CDI+ADHD 
 
Test Statistic  
Childhood_IA .94 3.12 ± 2.94 7.56 ± 1.26 [t(47.48) = -7.88 p < .001] 
Childhood_HI .92 2.71 ± 2.14 6.12 ± 2.55 [t(57) = -5.58 p < .001] 
Childhood_Total .96 5.83 ±  4.61 13.68 ± 3.13 [t(57) = -7.36 p < .001] 
Adult_IA .87 2.44 ± 1.89 6.2 ± 2.12 [t(57) = -7.15 p < .001] 
Adult_HI .84 2.85 ± 2.11 5.32 ± 2.38 [t(57) = -4.21 p < .001] 
Adult_Total .91 5.29 ± 3.61 11.52 ± 3.03 [t(57) = -6.99 p < .001] 
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Table 3: Scores of HC, CDI and CDI+ADHD on the total and subscales of the BIS-11 
Data are presented as means ± SD. 
 HC CDI CDI+ADHD Test statistic while controlling for IQ Post-hoc effects of group 
BIS_Total 54.29 ± 8.79 68.56 ± 9.42 78.60 ± 8.08 [F(2,83) = 34.41, p < .001] HC<CDI<CDI+ADHD 
BIS_Motor 19.04 ± 3.50 24.44 ± 4.84 27.16 ± 4.19 [F(2,83) = 19.52, p < .001] HC<[CDI=CDI+ADHD] 
BIS_Attention 12.89 ± 2.41 17.73 ± 3.88 19.28 ± 3.18 [F(2,83) = 15.43, p <. 001] HC<[CDI=CDI+ADHD] 
BIS_Non-planning  22.36 ± 4.01 26.68 ± 4.32 31.76 ± 4.02 [F(2,83) = 25.91, p < .001] HC<CDI<CDI+ADHD 
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3.2.1.2. Neurocognitive tasks 
Impulsive action 
Stop Signal Task: The mean probability of successful inhibition on stop trials was 50% and no 
participants were identified whose inhibition accuracy deviated 10% or more from the targeted 50%, 
indicating that the dynamic tracking algorithm worked well for all subjects. Significant group differences 
were found in SSRTs, which remained significant while controlling for the effects of IQ (see Table 4) or 
years of education (p < .001). Post-hoc analyses showed that SSRTs were significantly longer in the 
two clinical groups compared to the HC (see Fig.1). However, slowed processing of the stop-stimulus 
is in itself not informative with regard to the primacy of disinhibition, since it could equally well reflect 
an impairment of attention to the stop-signal. As such, the slowed processing of the stop-stimulus was 
studied in relation to the processing speed of the go-stimuli (i.e., mean go-signal reaction times, MRT). 
Although we found a trend towards a group effect on MRTs, a post-hoc ANCOVA revealed that group 
effects on SSRTs remained significant after controlling for these differences (F(2,83) = 10.14, p < .001). 
The effect of mean go-signal RTs as a covariate on SSRTs was far from significant (p = .91). 
Accordingly, a specific lack of inhibitory control rather than a deficit in attention underlies the difference 
between CDI and HC. The two clinical groups did not significantly differ from one another in terms of 
SSRTs (p = .81). Finally, a significant main effect of group was found for the intra-individual coefficient 
of variance (CV) (see Table 4). Post-hoc analyses revealed significantly greater reaction time 
variability in CDI+ADHD relative to HC (p = .019). A non-significant trend towards greater reaction time 
variability in the comorbid relative to the CDI-only group was further found (p = .07). 
 
 
Insert Figure 1 
Fig. 1. Mean go-stimuli RTs (response latency) and mean SSRT (stopping latency) for HC, CDI and CDI+ADHD. 
 
Impulsive choice 
Delay Discounting Task: Delay discounting rates (k-values) were estimated by nonlinear regression 
using Mazur’s hyperbolic model.  Figure 2 represents the fitted hyperbolic discounting curves on the 
mean indifference points per group. The discounting equation (hyperbolic model) provided a good fit to 
the data, accounting for 95%, 88%, and 83% of the variance for HC, CDI, and the CDI+ADHD, 
respectively. Because of positively skewed distributions of discounting coefficients, natural logarithm-
transformed k values were estimated = ln(k+0.001) and employed in the analyses of discounting. All k-
based analyses presented hereafter are based on the log-transformed values. Analysis of variance 
comparing transformed k-values for all three groups revealed a significant main group effect, which 
remained significant while controlling for IQ (see Table 4). Similar results were obtained when years of 
education was entered as a covariate (p < .001). Bonferroni post-hoc tests were used to compare 
each group to every other. No significant difference in ln(k)-values between HC and CDI without 
ADHD was found (p = .28). However, we did find significantly higher ln(k)-values in the CDI+ADHD 
group as compared to the HC (p < .001). The comorbid group also had significantly higher discounting 
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scores relative to the CDI without ADHD (p < .001). Because the comorbid group was more likely to 
use multiple substances, a supplementary analysis of covariance was performed to assess the effects 
of poly-drug use. However, group differences in delay discounting remained significant while 
controlling for the effects of poly-drug use (F(1,56) = 17.40, p < .001, ES = .49).  
 
Insert Figure 2 
Fig. 2. Points represent the median indifference points at the 6 different delay intervals (i.e., 5, 30, 180, 365, 
1095, and 3650 days) for HC, CDI and CDI+ADHD. Lines show the best-fitting discounting functions generated by 
the hyperbolic model. The graphic demonstrates that CDI+ADHD show steeper discounting curves compared to 
the two other groups.  
 
Information Sampling Task: Figure 3 shows the average number of boxes opened per condition as a 
function of group. As expected, the number of boxes opened per condition was significantly related to 
the probability of making a correct choice at the point of decision (r = .98, p < .001). Therefore, we 
focus our main analyses on the P(correct) variable.  
P(correct): P(correct)-data were analyzed using a repeated measures ANOVA with condition 
(FW, DW) as within-subject variable and group as the between-subject variable. There was a 
significant main effect of condition (F(1,82) = 98.03, p < .001), due to subjects sampling less information 
in the DW condition compared to the FW condition. As such, participants tolerated more uncertainty 
(lower P(correct)) in the DW than in the FW condition and thus, demonstrated sensitivity to the task 
contingencies. Paired t-tests revealed that these significant differences in the degree of information 
sampling between the FW and DW conditions were present in all three groups (all p < .001), meaning 
that all groups were broadly sensitive to the altered reward characteristics of the two conditions and 
were motivated to win points. There was also a main effect of group (F(2,82) = 15.76, p < .001). Post-
hoc analysis (collapsed across condition) showed that, compared to controls, both CDI and 
CDI+ADHD tolerated significantly more uncertainty in their decisions (all p < .001). However, this 
group effect became non-significant while controlling for differences in IQ (F(2,81) = 2.81, p = .07). 
Finally, we found a significant condition*group interaction (F(2,82) = 4.48, p = .01), which remained 
significant after controlling for IQ (F(2,81) = 3.97, p = .02) or years of education (F(2,81) = 4.27, p = .02). 
The nature of the significant group*condition interaction term was elucidated by calculating a 
difference score for the number of boxes opened in the FW and DW conditions. Figure 4 displays box 
adjustment in the three groups, representing the degree to which subjects adjust their behavior to the 
reward contingencies. We found a significant group effect on box adjustment, due to greater box 
adjustment in HC than in the CDI (p < .001) and CDI+ADHD (p = .04). Although the main effect of 
group on box adjustment remained significant while controlling for IQ (see Table 4) or years of 
education (p < .001), the difference between HC and CDI+ADHD became non-significant (p = .07). 
Contrary to our expectations, we also found a trend towards greater box adjustment in the CDI+ADHD 
compared to the CDI (p = .06). When the two clinical groups were directly compared to one another in 
terms of their box adjustment, taking into account differences in poly-drug use, we found significantly 
higher levels of box adjustment in the CDI+ADHD relative to the CDI without ADHD (F(1,56) = 6.06, p = 
.02). 
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Insert Figure 3  
Fig. 3. Number of boxes opened in the fixed reward (FW) and in the decreasing win (DW) conditions of the IST 
for HC, CDI and CDI+ADHD. 
Insert Figure 4 
Fig. 4. Mean adjustment scores on the IST for HC, CDI and CDI+ADHD. 
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Table 4: Scores of HC, CDI and CDI+ADHD on neurocognitive tasks of impulsivity 
 HC CDI CDI+ ADHD Test statistic 
while controlling for IQ 
Post-hoc effects of group 
SST      
  SSRT 224.06 ± 33 277.61 ± 51.16 280.87 ± 69.32 [F(2,83) = 5.78, p = .004] HC<[CDI=CDI+ADHD] 
  MRT Go-stimuli  516.03 ± 123.75 483.30 ± 84.02 505.37 ± 81.66 [F(2,83) = 2.87, p = .06] - 
  CV .21 ± .04 .22 ± .06 .25 ± .04 [F(2,83) = 4.37, p = .016] CDI+ADHD>HC 
CDI+ADHD=CDI 
DDT      
  Ln(k) -6.50 ± .47 -6.35 ± .58 -5.36 ± 1.36 [F(2,83) = 15.22, p < .001] CDI+ADHD>[HC=CDI] 
IST      
  BoxesOpened (/25) 14.95 ± 3.93 10.43 ± 4.54 9.72 ± 3.45 [F(2,81) = 2.18, p = .12] (NS after controlling for IQ) 
  P(correct) .85 ± .08 .75 ± .09 .74 ± .07 [F(2,81) = 2.81, p = .07] (NS after controlling for IQ) 
  Box Adjustment 7.42 ± 5.19 2.88 ± 2.54 4.98 ± 4.89 [F(2,83) = 6.39, p = .003] CDI<[HC=CDI+ADHD] 
Data are presented as means ± SD. 
Abbreviations: CV: coefficient of variance, DDT: delay discounting Task, IST: information sampling task, Ln(k): natural log transformed k-values, MRT: mean reaction time, NS: non-significant: SSRT: 
stop signal reaction time, SST: stop signal task.
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3.2.1.3. Logistic regression analysis 
A logistic regression analyses was conducted, with the impulsivity variables that demonstrated 
significant differences between the CDI and CDI+ADHD (i.e., BIS-11 non-planning scores and ln(k)-
values) as the predictor variables. A test of a model combining these impulsivity variables as 
predictors against a constant only model was statistically significant, indicating that non-planning 
impulsivity and delay discounting reliably distinguished between CDI with and without ADHD (χ
2
(2) = 
29.83, p < .001), with 53% of the (pseudo)variance in ADHD status explained (Nagelkerke R square = 
.533). The model yielded an overall correct classification of 81.4 %, with a sensitivity and specificity of 
76% and 85.3%, respectively. 
3.2.2. Correlations among impulsivity measures 
Pearson product-moment correlations were calculated between impulsivity measures and cocaine use 
variables in the cocaine sample (n=59) and are presented in Table 5. We applied a Bonferroni 
correction to control for multiple comparisons, resulting in corrected alpha level of 0.005 (i.e., 0.05/10). 
All three BIS-11 subscales significantly correlated (p < .005) with the BIS-11 total scale. We found no 
significant correlations between trait and neurocognitive measures of impulsivity, with the exception of 
a trend towards a positive correlation between scores on the BIS-11 non-planning subscale and DDT 
k-values (p = .049). No correlations were found between scores on the SST, DDT and IST, which is 
consistent with the idea that response inhibition, delay discounting and reflection impulsivity reflect 
separate dimensions of impulsivity. Scores on the motor, non-planning and total BIS-11 scales 
negatively correlated with the age of onset of cocaine use.  
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Table 5: Correlations between impulsivity and drug use variables 
 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) 
(1) BIS_Motor 1          
(2) BIS_Attentional ,257 1         
(3) BIS_Non-planning ,511
*
 ,382
*
 1        
(4) BIS_Total ,814
*
 ,618
*
 ,820
*
 1       
(5) DDT_ln(k) -,040 ,007 ,257 ,101 1      
(6) SSRT -,051 -,082 -,018 -,050 -,031 1     
(7) IST_P(correct) ,052 -,087 -,066 -,047 ,035 ,029 1    
(8) Past month cocaine use ,074 ,121 ,043 ,125 -,281 -,061 -,183 1   
(9) Duration cocaine use ,352 ,120 ,302 ,356 -,224 ,029 ,030 ,116 1  
(10) Age of cocaine use onset -,371
*
 -,293 -,419
*
 -,485
*
 -,009 ,109 -,013 ,002 -,300 1 
* Correlation is significant at the p < .005 level (2-tailed) 
Abbreviations: DDT_ln(k): natural log transformation of the discount rate, SSRT: stop signal reaction time, IST_P(correct): probability of being correct at the time of decision on the IST.
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4. Discussion 
The present study evaluated the relationship between different facets of impulsivity and 
cocaine dependence and explored the effect of ADHD on this relationship. Both CDI with and without 
ADHD reported higher scores on the total and three subscales of the BIS-11 questionnaire (i.e., trait 
impulsivity) and required more time to inhibit motor responses on the SST (i.e., motor disinhibition) 
compared to healthy controls. While the increased impulsivity on these indices in CDI replicates 
previous findings [9,10], our study was the first to demonstrate that CDI (with and without ADHD) also 
sample less information on the IST prior to making a decision (i.e., reflection impulsivity) when 
compared to HC. With the exception of differences in reflection impulsivity, the increased impulsivity in 
the cocaine groups remained significant while controlling for differences in IQ. Overall, these findings 
indicate that CDI display and report higher levels of impulsivity than HC on a variety of impulsivity 
measures, regardless of whether or not they have a comorbid ADHD diagnosis. There was however 
one exception to this finding. Specifically, we found that only CDI+ADHD and not those without an 
ADHD diagnosis showed a more pronounced intolerance to delay-of-gratification on the DDT 
compared to HC. This finding in other words indicates that higher levels of delay discounting in CDI 
are specifically associated with the presence of ADHD or, at minimum, that steeper discounting of 
delayed rewards is a hallmark characteristic of the comorbidity between cocaine dependence and 
ADHD. Partially supporting this latter notion, a recent study found that, relative to HC, only ADHD 
patients with and not those without cocaine dependence were characterized by elevated levels of 
delay discounting [51]. These findings may suggest that chronic cocaine use interacts with the 
pathophysiology underlying ADHD to produce more pronounced and clinically significant discounting 
scores. Consequently, future studies examining delay discounting in CDI but also in subjects with an 
ADHD diagnosis should take into account the effects that either ADHD or cocaine dependence may 
have on delay reward discounting in these groups 
The current study was also the first to directly compare scores on trait and neurocognitive 
measures of impulsivity between CDI with and without ADHD. We found that two specific indices of 
impulsivity, BIS-11 non-planning impulsivity and delay discounting respectively, were able to 
differentiate CDI from CDI with an ADHD diagnosis, with an overall classification accuracy of 81.4%. 
Our results more specifically suggest that ADHD may exert synergistic detrimental effects on the 
ability to plan ahead or orient towards future, rather than to immediate rewards in CDI. The higher 
scores on non-planning and choice impulsivity in the CDI+ADHD relative to the non-comorbid group of 
CDI remained significant while controlling for the effects of poly-drug use, which was higher in the 
comorbid group. Because other drug use characteristics did not differ between the two clinical groups, 
our findings suggest that drug use itself may not have accounted for the observed differences in 
impulsivity. These data are generally consistent with previous reports suggesting that trait impulsivity 
reflects a disposition that is present prior to the initiation of drug use [52] and with findings indicating 
that delay discounting is unaffected by drug use and/or abstinence [12,53,54,55]. As such, higher non-
planning impulsivity and delay discounting in the comorbid group may have predated drug use, 
proportionally increasing the risk of developing a SUD. Alternatively, individuals with ADHD may be 
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more vulnerable for cocaine-induced catecholaminergic disruptions as a result of the pathophysiology 
underlying ADHD, even if amount and duration of cocaine use are similar to non-comorbid CDI [56]. 
Clearly, more research (longitudinally) is needed to evaluate the temporal relationship between non-
planning impulsivity, delay discounting, ADHD and cocaine dependence. 
In contrast with the disparities in delay discounting, indices of impulsivity on the SST (i.e., SSRT) and 
IST (i.e., P_correct) did not reveal any differences between the two cocaine subgroups. In light of the 
generally held view that poor response inhibition represents a core deficit in ADHD 
[57,58,59,60,61,62,63], the absence of differences in SSRTs between both groups was perhaps most 
surprising. Several potential explanations may account for this rather unexpected finding. Because 
individuals with low or moderate levels of dopamine transmission have previously been found to show 
benefits from stimulant drugs, cocaine use may have potentially enhanced the ability of subjects with 
ADHD to inhibit behavioral responses [64,65,66]. However, the fact that all subjects in our sample 
were abstinent for at least three days makes this interpretation less likely. Indeed, abstinence from 
drugs has been associated with decreased dopaminergic transmission in the prefrontal cortex and 
anterior cingulate, thereby impairing rather than enhancing response inhibition [64,67]. Some authors 
have also proposed the existence of two subtypes of ADHD, which lead to the generation of ADHD 
symptoms via two distinct pathways: the altered “motivational style” pathway, which generates a 
strong aversion to delays, and the disordered “thought and action” pathway, which leads to a more 
fundamental dysregulation of inhibitory control [68]. The former subtype has been suggested to arise 
through alterations in brain areas involved in reward processing, including the ventral striatum, and 
innervated by the mesolimbic branch of the dopamine system [68]. Hypothetically, subjects with this 
subtype may be more likely to engage in substance use behavior, explaining why our comorbid group 
was specifically characterized by greater delay discounting rather than poor inhibition. This notion 
would cohere with the growing recognition of excessive delay discounting as a trans-disease process 
[69]. It also remains possible that previous studies have overestimated the centrality of poor inhibitory 
control in subjects with ADHD, and that deficits related to motor inhibition are more specific to cocaine 
dependence than to ADHD [51]. Impairments in other aspects of response control on the other hand, 
including increased intra-subject variability in response times, might be more central to ADHD 
[70,71,72]. Finally, because both samples consisted of cocaine-dependent patients, i.e. a population 
that is by definition characterized by impaired inhibitory control, it remains possible that the absence of 
significant differences in SSRTs between the two clinical groups reflect a ceiling effect. 
 
Clinical implications 
Despite the overall descriptive nature of the current study, the findings presented here highlight 
several interesting directions for future (research) efforts aimed at improving the assessment and 
treatment of ADHD in CDI. The overall good discriminatory ability of the BIS-11 non-planning scale 
and DDT, combined with their brevity and ease of administration, suggests that these indices could be 
explored as clinical tools for brief screening in clinical settings. If well constructed and widely available, 
these screeners could serve to guide professionals in their referrals for assessment and treatment of 
ADHD in CDI. In contrast to a purely categorical perspective on ADHD, incorporating a dimensional 
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classification based on impulsivity scores may be of greater clinical utility in terms of predicting 
treatment outcomes, treatment planning and selection. Future studies aimed at developing norms and 
establishing clinically-relevant cut-off points may substantially help the clinical field moving forward in 
this respect. 
During the past decades, several studies have found the presence of ADHD among CDI to be 
associated with worse addiction treatment outcomes, including higher rates of premature treatment 
drop-out and a greater propensity to relapse [31,36,37,73]. To date however, the mechanisms 
mediating the negative effects of ADHD on addiction treatment outcomes remain unexplored. A 
worthwhile prospect for future studies may therefore be to explore whether elevated impulsivity among 
CDI with ADHD accounts for their increased risk for treatment failure. Such a finding would be 
consistent with growing evidence indicating that non-planning impulsivity and delay discounting place 
drug users at higher risk for relapse or premature treatment drop-out [74,75] and would contribute to 
the isolation of possible mechanisms for intervention approaches.  
 
Limitations 
Several limitations of this study should be highlighted. First, healthy controls were not matched to the 
clinical groups in terms of IQ or years of education. Still, most of our findings remained significant 
when controlling for these variables. Second, our samples were relatively small. As such, subtle 
differences in performance between the two clinical groups may not have been detected. At the same 
time, this implies that the observed differences in impulsivity between CDI with and without an ADHD 
diagnosis represent relatively large effects, with effect sizes of .50 and .49 for non-planning and delay 
discounting respectively. Third, Cronbach's alpha of the BIS-11 attentional impulsivity subscale was 
poor in the current sample (i.e., .39). Given the low internal consistency, the observed between-group 
differences on this scale should be interpreted with appropriate caution. Fourth, our research 
diagnoses of ADHD were based entirely on self-report from participants, as opposed to diagnoses 
obtained from a comprehensive diagnostic assessment procedure. Still, adults have shown the ability 
to accurately rate childhood ADHD symptomatology [76]. Moreover, we used the more stringent cut-off 
score of 6 symptoms and focused on whether the reported symptoms were associated with 
impairment and whether impairment occurred in at least two situations. Our sample was composed 
entirely of individuals who reported cocaine as their primary substance of abuse; results may therefore 
not be representative of individuals seeking treatment for non-stimulant drugs (e.g., opioids, cannabis). 
Similarly, the CDI in our sample were patients with a high problem severity, as exemplified by low IQ 
and a need for inpatient treatment, warranting careful consideration when considering other groups of 
CDI. Finally, although we used a test battery measuring different core dimensions of impulsivity, not all 
impulsivity aspects were covered. For instance, we did not measure cognitive inhibition, which refers 
to the ability to suppress competing, distracting information. As preliminary evidence suggests that 
drug consumption in individuals with ADHD is associated with poor attentional inhibition in particular 
[77], future studies may benefit from including a measure of interference control while comparing CDI 
with and without ADHD.  
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